logo
Twitter
Discord
Email
logo
Sanofi

Sanofi

NASDAQ•SNY
CEO: Mr. Paul Hudson
Sector: Healthcare
Industry: Drug Manufacturers - General
Listing Date: 2002-07-01
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Contact Information
46, avenue de la Grande Armée,, Paris, 75017, France
33-1-53-77-40-00
www.sanofi.com
Market Cap
$113.51B
P/E (TTM)
10.6
23.6
Dividend Yield
4.9%
52W High
$60.12
52W Low
$44.62
52W Range
13%
Rank30Top 19.5%
5.1
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.1 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q3 2025 Data

Revenue

$15.40B-6.97%
4-Quarter Trend

EPS

$1.34+1.77%
4-Quarter Trend

FCF

$0.00+0.00%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Strong Biopharma Net Sales Net sales reached €41.08B in 2024, increasing 8.6% reported, driven by 11.3% growth at constant exchange rates.
Dupixent Sales Momentum Continues Dupixent generated €13.07B in 2024 sales, showing 22.0% reported growth, reflecting strong demand across approved indications.
New Launches Drive Growth New launches like Beyfortus reached €1.69B sales in 2024, achieving triple-digit growth and offsetting legacy product declines.
Operating Income Improvement Operating income rose to €7.25B in 2024, up from €6.96B in 2023, despite increased R&D investment of €7.39B.

Risk Factors

Pricing Pressure and Reimbursement Operating in volatile market facing high cost containment pressures globally, including US IRA negotiations and China VBP tenders.
R&D Pipeline Execution Risk Developing new medicines is costly and uncertain; failure to meet R&D KPIs or launch targets could adversely affect portfolio renewal.
Legal and Regulatory Exposure Defending multiple product liability claims (Taxotere, Zantac, Depakine) carries risk of substantial damages impacting financial condition.
Cybersecurity and Data Governance Risks Business heavily relies on IT systems, vulnerable to cyberattacks, data breaches, and risks associated with evolving AI technology governance.

Outlook

Opella Divestiture Finalization Exclusive negotiations with CD&R for Opella sale expected to close in Q2 2025, focusing capital allocation on innovative medicines.
Increased R&D Investment Focus Intent to increase R&D spend, focusing strategy on Immunology, Rare Diseases, Neurology, and selectively in Oncology for future growth.
Disciplined Capital Allocation Policy Priorities include organic growth investment, bolt-on M&A, growing annual dividend, and anti-dilutive share buybacks.
Manufacturing Capacity Expansion Major investment plans exceeding €1.1B announced for 2024 to increase bioproduction capacity, including new Modulus unit.

Peer Comparison

Revenue (TTM)

CVS Health CorporationCVS
$394.08B
+6.8%
HCA Healthcare, Inc.HCA
$74.37B
+6.8%
Pfizer Inc.PFE
$62.79B
+3.9%

Gross Margin (Latest Quarter)

Vertex Pharmaceuticals IncorporatedVRTX
86.5%
+0.7pp
Gilead Sciences, Inc.GILD
79.8%
+0.7pp
Pfizer Inc.PFE
74.9%
+14.1pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
AMGN$177.92B25.496.2%60.6%
GILD$154.97B19.140.7%42.6%
PFE$145.84B14.810.9%29.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
23.7%
Strong Growth
4Q Net Income CAGR
83.3%
Profitability Improved
Cash Flow Stability
25%
Cash Flow Needs Attention

Research & Insights

Next earnings:Jan 29, 2026
|
EPS:$0.83
|
Revenue:$11.13B
Reports
All Years
  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Feb 13, 2025|
    Revenue: $47.91B+6.4%
    |
    EPS: $2.37+1.9%
    Beat
  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Feb 23, 2024|
    Revenue: $45.02B+2.6%
    |
    EPS: $2.33-32.3%
    Beat
  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Feb 24, 2023|
    Revenue: $42.64B+3.5%
    |
    EPS: $3.35+28.2%
    Beat
  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Feb 23, 2022|
    Revenue: $46.32B+4.8%
    |
    EPS: $2.94-49.4%
    Miss
  • Form 20-F - FY 2020

    Period End: Dec 31, 2020|Filed: Mar 4, 2021|
    Revenue: $42.62B-0.7%
    |
    EPS: $5.60+330.7%
    Meet